Ma Fei, Xu Binghe, Lin Dongxin, Sun Tong, Shi Yuankai
Department of Medical Oncology, Cancer Institute & Hospital, Chinese Academy of Medical Science, Peking Union Medical College, Beijing 100021, China.
Zhongguo Fei Ai Za Zhi. 2011 Aug;14(8):642-5. doi: 10.3779/j.issn.1009-3419.2011.08.02.
Genetic variations of the epidermal growth factor receptor (EGFR) may alter the protein function and therapeutic efficacy of EGFR inhibitors. The aim of this study is to investigate the association between single nucleotide polymorphism rs2293347 in EGFR and the clinical outcome in patients with advanced non-small cell lung cancer (NSCLC) treated with gefitinib.
A total of 88 advanced NSCLC patients treated with gefitinib were analyzed in the present study. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was conducted to analyze the genotype. The association study was performed between genotypes and clinical efficacy among 88 patients.
rs2293347 was associated with the efficacy of gefitinib. The response rate for the rs2293347 GG was significantly higher than that for the GA or AA (71.4% vs 36.0%, P=0.002). rs2293347 GG genotype was also associated with longer progression-free survival compared with GA or AA genotype (10 months vs 3 months, P=0.005). No significant difference was shown on the overall survival (OS) (P=0.409).
rs2293347 polymorphism in exon 25 is associated with the clinical efficacy of gefitinib and may be a potential biomarker to predict the clinical outcome in advanced NSCLC patients treated with gefitinib.
表皮生长因子受体（EGFR）的基因变异可能会改变EGFR抑制剂的蛋白质功能和治疗效果。本研究旨在探讨EGFR单核苷酸多态性rs2293347与接受吉非替尼治疗的晚期非小细胞肺癌（NSCLC）患者临床结局之间的关联。
本研究共分析了88例接受吉非替尼治疗的晚期NSCLC患者。采用聚合酶链反应-限制性片段长度多态性（PCR-RFLP）方法分析基因型。对88例患者的基因型与临床疗效进行关联研究。
rs2293347与吉非替尼的疗效相关。rs2293347 GG基因型的缓解率显著高于GA或AA基因型（71.4%对36.0%，P = 0.002）。与GA或AA基因型相比，rs2293347 GG基因型也与更长的无进展生存期相关（10个月对3个月，P = 0.005）。总生存期（OS）无显著差异（P = 0.409）。
第25外显子中的rs2293347多态性与吉非替尼的临床疗效相关，可能是预测接受吉非替尼治疗的晚期NSCLC患者临床结局的潜在生物标志物。
